AstraZeneca and Vodafone enter partnership to improve cardiovascular health

By Admin
The recent announcement of a global partnership between Vodafone and the UKs AstraZeneca is bent on assisting patients with serious cardiovascular condi...

The recent announcement of a global partnership between Vodafone and the UK’s AstraZeneca is bent on assisting patients with serious cardiovascular conditions. This relationship will work with various healthcare professionals using mobile technology to increase patient communication capabilities: both mHealth and internet-based mHealth services.

Taking lead on the project, AstraZeneca’s Intelligent Pharmaceutical Group will spearhead the project’s management and development components, with Vodafone’s technology, infrastructure and expertise as the backbone behind its ideas.

Vodafone’s Director for its Machine to Machine program stated, “Bringing together the best in connectivity with the best in treatment and education will create powerful and compelling outcomes for patients. AstraZeneca is a global leader in the mHealth field and we are delighted to work with them to develop these innovative services.”

Share

Featured Articles

Philip Morris International (PMI) in agreement with KT&G

PMI and KT&G are building a smoke-free world. In a new agreement between the two companies, smoke-free alternatives are within reach for smokers

Health tech leader Philips shares sustainability ambition

Roy Jakobs, Royal Philips CEO, says the health technology company’s sustainability impact plan will ‘enhance accountability & strengthen talent’

Automating gene therapy & pharma discovery at Automata

Sonia Jassi, Drug Discovery & Synthetic Biology Lead at Automata, explains how automation increases efficiency in gene therapy laboratories

Itai Hayut, CEO of Scopio Labs, on AI & blood cancer

Technology & AI

2023 predictions with Harshit Jain, global CEO of Doceree

Telehealth & COVID-19

Wolters Kluwer Health: health equity and telehealth

Telehealth & COVID-19